News / Social Media
January 2025
In the Communications of the German Society of Nephrology, the current status of clinically applicable biomarkers in the context of chronic kidney disease was presented with a focus on early detection, prognosis, and differential diagnosis. Based on two recently published review articles from the UPTAKE consortium on non-invasive biomarkers for chronic kidney disease patient management, a prominent role of multiple applications of Mosaiques’ biomarkers and technology was presented.
Both articles are available online in the "International Journal of Molecular Science" at https://www.mdpi.com/1422-0067/25/7/3678 and https://www.mdpi.com/1422-0067/25/6/3519 respectively.
December 2024
The EU Commission has engaged an independent analysis team to assess the market potential of 13,000 innovations funded under the Horizon program. Among these, the urine diagnostic technology of proteome analysis—used to determine the individual effects of drugs through in-silico modeling—has been recognized as “market-ready” and a “key innovation” with “high market creation potential".
More information can be found here.
November 2024
Board members of statutory health insurance funds and health politicians from the Bundestag will meet on 26.11.2024 to discuss with mosaiques/protexam the future of the healthcare system to discuss in Germany.
The molecular - first-time - disease determination and early detection of chronic diseases prevents organ damage and avoids pandemics such as Covid-19 caused by SARS-CoV-2 and other viruses that are now approaching us. The chronic diseases cause damage to the endothelium (cells of the inner walls of blood vessels) and scarring due to inflammation (fibrosis), which accompany the chronic diseases and can lead to serious courses of viral infections. This is the core theme of the health policy of Robert F. Kennedy Jr., the designated US Secretary of Health.
Proteomic analysis has proven its clinical benefits in well over 100 studies involving 1,200 renowned physicians and scientists, published in over 400 high-ranking scientific journals. Without proteomic analysis, no solution to this dilemma of humanity is possible.
February 2024
- Krankenkasseninfo.de reported on 28.02.2024 about the protexam tests reported.
- The Berliner Zeitung reported on 28.02.2024 about the protexam tests.
- The Bild newspaper reported on 03.02.2024 about the protexam tests.
- The first statutory health insurance company (The Innovation Fund) takes responsibility for its insured persons and enables them to test
protexam for the early detection of diseases. This helps to prevent chronic diseases and cancer through the early application of appropriate therapies.